Skip to main content
×
×
Home

Historical perspective on antipsychotic long-acting injections

  • D. A. W. Johnson (a1)
Abstract
Background

Clinical experience has shown considerable potential benefits from long-term continuous medication for chronic or relapsing forms of schizophrenia. These benefits have not always been realised.

Aims

To review the research literature in order to understand the problems of long-term medication and use of antipsychotic oral medication and long-acting injections (LAIs), and to place these in an historical context.

Method

Review of literature.

Results

Research showed that the potential success of LAI therapy depends on the quality of the follow-up service.

Conclusions

Following the advent of second-generation oral antipsychotics confidence in the use of LAIs has eroded and that mistakes made in LAI use during the past century may be repeated.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Historical perspective on antipsychotic long-acting injections
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Historical perspective on antipsychotic long-acting injections
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Historical perspective on antipsychotic long-acting injections
      Available formats
      ×
Copyright
References
Hide All
1 Delay, J, Deniker, P. Trente-huit cas de psychoses traités par le cure prolongé et continue de 4560RP. Le Congrès des Al. et Neurol. de Langue Fr. Comptes Rendus du Congres Paris. Masson, 1952.
2 Scarpitti, FR, Pasamanick, BS. Medication in schizophrenia. Arch Gen Psychiatry 1964; 10: 143.
3 Prien, RF, Cole, JO, Belkin, NF. Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. Br J Psychiatry 1969; 115: 679–86.
4 Denham, J, Adamson, L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 1971; 47: 420–30.
5 Johnson, DAW, Freeman, HL. Long-acting tranquillisers. Practitioner 1972; 208: 395400.
6 Gottfries, GC, Green, L. Fluphenthixol decanoate – in treatment of outpatients. Acta Psychiatr Scand Suppl 1974; 225: 1524.
7 Hogarty, GE, Goldberg, SC, Schooler, NR. Drug and sociotherapy in the aftercare of schizophrenic patients: one year relapse rates. Arch Gen Psychiatry 1973; 28: 5464.
8 Hogarty, GE, Goldberg, SC, Schooler, NR. Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch Gen Psychiatry 1974; 31: 603–8.
9 Hogarty, GE, Ulrich, R, Goldberg, SC. Sociotherapy and the prevention of relapse among schizophrenic patients. In Evaluation of Psychological Therapies (eds Spitzer, RL, Klein, DF): 285–93. Johns Hopkins University Press, 1976.
10 Hirsch, SR, Gaind, R, Rhode, PD, Stevens, BC, Wing, JK. Outpatient maintenance of chronic schizophrenic patients with long acting phenothiazines. BMJ 1973; i: 633–7.
11 Davis, JM. Overview: maintenance therapy in schizophrenia. I. Schizophrenia. Am J Psychiatry 1975; 132: 1237–45.
12 Rifkin, A, Quitkin, F, Rabiner, CJ. Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenia: relapse rate over one year. Arch Gen Psychiatry 1977; 34: 43–7.
13 Quitkin, F, Rifkin, A, Kane, J, Ramos-Lorenzi, JR, Klein, DF. Long-acting oral drugs vs. injectable antipsychotic drugs in schizophrenia: a one year double-blind comparison in multi episode schizophrenia. Arch Gen Psychiatry 1978; 35: 889–92.
14 Schooler, NR, Levine, J, Severe, JB, Brauzer, B, DiMascio, A, Klerman, GL, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980; 37: 1624.
15 Tegeler, J, Lehmann, E. A follow-up study of schizophrenic outpatients treated with depot neuroleptics. Prog Neuropsychopharmacol 1981; 5: 7990.
16 Wistedt, B. A neuroleptic withdrawal study in chronic schizophrenic patients. Acta Psychiatr Scand 1981; 64: 6584.
17 Kane, JM, Rifkin, A, Quitkin, F, Nayak, DV, Ramos-Lorenzi, JR. Fluphenazine versus placebo in patients with remitted, acute first episodes of schizophrenia. Arch Gen Psychiatry 1982; 39: 70–3.
18 Johnson, DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand Suppl 1983; 63 (suppl 290): 447–53.
19 Johnson, DAW. Observations on the use of long-acting depot neuroleptic injections in the maintenance treatment of schizophrenia. J Clin Psychiatry 1984; 45: 1321.
20 Crow, TJ, McMillan, JF, Johnson, AL, Johnstone, EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120–7.
21 Pietzcker, A, Gaebel, W, Kopcke, W, Linden, M, Muller, P. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatry 1986; 19: 161–6.
22 Hogarty, GE, Schooler, NR, Ulrich, R, Mussare, F, Ferro, P, Herron, E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283–94.
23 Kissling, W, (ed). Neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: 50–2. Springer, 1991.
24 Johnson, DAW. United Kingdom: neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W): 45. Springer, 1991.
25 Dencker, SJ. Sweden: neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W): 24. Springer, 1991.
26 Fleischhacker, WW, Meise, U. Austria: the current status of maintenance treatment in schizophrenia. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W): 13. Springer, 1991.
27 Cooper, B, Shepherd, M. Life change, stress and mental disorder: the ecological approach. In Modern Trends in Psychological Medicine, 2nd edn (ed Price, JH): 102–30. Butterworth, 1970.
28 Pinel, P. A Treatise on Insanity (trans. Davis, D.). History of Medicine Series No. 14. Hafner, 1962.
29 Kendal, RE, Pighot, P, von Cranach, M. Diagnostic criteria of English, French and German psychiatrists. Psychol Med 1974; 4: 187–95.
30 Kendal, RE. The classification and phenomenology of schizophrenia: overview. In Contemporary Issues in Schizophrenia (ed Kerr, A, Snaith, P): 119–23. Gaskell, 1986.
31 Feigher, JP, Robins, E, Guze, S, Woodruff, RA, Winokur, G, Munoz, R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972; 26: 5763.
32 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). APA, 1980.
33 Leff, JP, Wing, JK. Trial of maintenance therapy in schizophrenia. BMJ 1971; 3: 599604.
34 World Health Organization. The International Pilot Study of Schizophrenia, vol. 1. WHO, 1974.
35 Mandelbrote, BM. Schizophrenia: treatment and outcome. In Modern Trends in Psychological Medicine, 2nd edn (ed Price, JH): 200–22. Butterworth, 1970.
36 Greenblatt, M, York, RH, Brown, EL. From Custodial to Therapeutic Care in Mental Hospital. Russell Sage Foundation, 1955.
37 Bockhoven, JS. Moral treatment in American society. J Nerv Ment Dis 1956; 124: 167.
38 Standt, VM, Zubin, J. A biometric evaluation of the somatotherapies in schizophrenia – a critical review. Psychol Bull 1957; 5: 171.
39 Moniz, E. Tentatives Operatoires dans le Traitement de Certaines Psychoses. Masson, 1936.
40 Appel, KE, Lhamon, WT, Myers, JM, Harvey, WA. Long-term psychotherapy in psychiatric treatment. Res Publ Assoc Res Nerv Ment Dis 1953; 31: 2141.
41 Wing, JK, Brown, GW. Social treatment of chronic schizophrenia: a comparative study of three mental hospitals. J Ment Sci 1961; 107: 847–61.
42 Birley, JLT, Brown, GW. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. Br J Psychiatry 1970; 116: 327–33.
43 Bebbington, PE, Kuipers, L. Social influences on schizophrenia. In Schizophrenia: The Major Issue (eds Bebbington, P, McGuffin, P): 202–25. Heinemann, 1988.
44 Greenblatt, M. Drugs in Combination with Other Therapies. Grune & Stratton, 1975.
45 Bebbington, P, McGuffin, P, (eds). Schizophrenia: The Major Issues. Heinemann, 1988.
46 Taylor, RDW, Huxley, PJ, Johnson, DAW. The role of social networks in the maintenance of schizophrenic patients. Br J Social Work 1984; 14: 129–40.
47 Freeman, HL, (ed). Psychiatric Hospital Care. Baillière Tindall & Cassell, 1965.
48 Freeman, HL, Johnson, DAW. Progress to community care in an English city Pakistan Medical Forum 1970; 5: 2534.
49 Davis, JM, Schaffer, CB, Kinard, C, Chan, C. Important issues in drug treatment of schizophrenia. Schizophr Bull 1980; 6: 7087.
50 Kane, JM. Treatment of schizophrenia. Schizophr Bull 1987; 13: 133–56.
51 Barnes, TRE, Hirsch, SR. Neuroleptic relapse prevention. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W). Springer, 1991.
52 Brown, GW, Birley, JLT, Wing, JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 1972; 121: 241–58.
53 Vaughn, CE, Leff, JP. The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129: 125–37.
54 Hogarty, GE, Goldberg, SC, Schooler, NR. Drug and sociotherapy in the aftercare of schizophrenic patients. In Drugs in Combination with Other Therapies (ed Greenblatt, M): 134. Grune & Stratton, 1975.
55 Cutting, J. Outcome of schizophrenia: overview. In Contemporary Issues in Schizophrenia (eds Kerr, A, Snaith, P): 433–40. Gaskell, 1986.
56 Ley, P, Spelman, MS. Communicating with the Patient: 3778. Staples Press, 1967.
57 Wilcox, DRC, Gillan, R, Hare, EH. Do psychiatric patients take their drugs? BMJ 1965; 2: 790–2.
58 Neve, HK. Demonstration of Largactil in the urine. J Ment Sci 1958; 104: 488–91.
59 Johnson, DAW. Treatment of depression in general practice. BMJ 1973; 2: 1820.
60 Johnson, DAW. A study of the use of antidepressant medication in general practice. Br J Psychiatry 1974; 125: 186–92.
61 Johnson, DAW, Freeman, HL. Drug defaulting by patients on long-acting phenothiazines. Psychol Med 1973; 3: 115–9.
62 Baldessarini, RJ, Cohen, BM, Teicher, MH. Significance of neuroleptic dose and plasma level in the pharmacological treatments of psychoses. Arch Gen Psychiatry 1988; 45: 7981.
63 Hogarty, GE, Ulrich, RF, Mussare, F, Austigueta, N. Drug discontinuation among long term successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976; 37: 494500.
64 Wistedt, B. A depot neuroleptic withdrawal study. Acta Psychiatr Scand 1981; 64: 6584.
65 Marder, SR, van Putten, R, Mintz, J, Lebell, M, McKenzie, J, May, PRA. Low and conventional maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987; 44: 518–22.
66 Kissling, W, Kane, JM, Barnes, TRE, Dencker, ST, Fleischhacker, WW, Goldstein, MJ, et al. In Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (ed Kissling, W). Springer, 1991.
67 Johnson, DAW. The side-effects of fluphenazine decanoate. Br J Psychiatry 1973; 123: 519–22.
68 Johnson, DAW. Long term drug treatment of psychoses: observations on some current issues. Int Rev Psychiatry 1990; 2: 341–53.
69 British Medical Association, Royal Pharmaceutical Society. British National Formulary. Antimuscarinic Drugs 4.9.2. BMJ Books/Pharmaceutical Press, 2008.
70 Johnson, DA. Studies of depressive symptoms in schizophrenia. Br J Psychiatry 1981; 139: 89101.
71 Johnson, DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988; 152: 320–3.
72 Johnson, DAW. Long term treatment of psychoses; observations on some current issues. Int Rev Psychiatry 1990; 2: 341–53.
73 McGlashen, TH, Carpenter, WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33: 231–39.
74 McGlashen, TH, Carpenter, WT. An investigation of the postpsychotic depressive syndrome. Am J Psychiatry 1976; 133: 14–9.
75 Knights, A, Hirsch, SR. Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry 1981; 38: 806–11.
76 Mandel, MR, Severe, JB, Schooler, NR. Development and prediction of postpsychotic depression in neuroleptic treated schizophrenia. Arch Gen Psychiatry 1982; 39: 197203.
77 Roy, A. Risk factor for suicide in psychiatric patients. Arch Gen Psychiatry 1982; 39: 1089–95.
78 Van Putten, T, May, PRA. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978; 45, 1101–7.
79 Herz, MI, Melville, C. Relapse in schizophrenia. Am J Psychiatry 1980; 137: 801–5.
80 Carpenter, WR, Heinrich, DW, Hanlon, TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144: 1466–70.
81 Brockington, IF, Kendell, RE, Kellett, JM, Curry, SH, Wainwright, S. Trial of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 1978; 133: 162–8.
82 Brockington, IF, Kendell, RE, Leff, JP. Prognostic implications of six alternative definitions of schizophrenia. Arch Gen Psychiatry 1979; 36: 2531.
83 Siris, SG. Antidepressants in ‘depressed’ schizophrenics. In Depression in Schizophrenia (eds Williams, R, Dalby, JT): 215–32. Plenum, 1989.
84 Johnson, DAW, Wright, NK. Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry 1990; 156:827–34.
85 Johnson, DAW, Rasmussen, JGC. Professional attitudes in the UK towards neuroleptic maintenance therapy in schizophrenia. The problem of inadequate prophylaxis. Psychiatr Bull 1997; 21: 394–7.
86 Kissling, W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry 1992; 161 (suppl 18): 133–9.
87 Cassey, DS. Relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 (suppl 10): 5562.
88 Correl, CU, Leucht, S, Kane, JM. Lower risk for TD associated with secondary generation antipsychotics; a systematic review of 1 year studies. Am J Psychiatry 2004; 161: 414–25.
89 Bagnall, AM, Jones, L, Ginelly, L, Lewis, R, Glanville, J, Gilbody, S, et al. A systematic review of atypical antipsychotics in schizophrenia. Health Technol Assess 2008; 7: 13.
90 Jones, PB, Barnes, TRE, Davies, L. Randomised controlled trial of the effect on quality of life of second vs first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079–87.
91 Shirzadi, AA, Ghaemi, SN. Side-effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14: 152–64.
92 Blom-Cooper, LJ, Hally, H, Murphy, E. The Falling Shadow: One Patient's Mental Healthcare 1978–1993. Report of the Committee of Inquiry into the Events Leading up to and Surrounding the Fatal Incident at the Edith Morgan Centre, Torbay, on 1 September 1993. Duckworth, 1995.
93 Thornicroft, G. National Service Framework for Mental Health. Psychiatr Bull 2000; 24: 203–6.
94 Patel, M, Nikolaou, V, David, AS. Eliciting psychiatrists' beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract 2003; 7: 117–20.
95 Patel, MX, David, AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2005; 11: 203–11.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 19 *
Loading metrics...

Abstract views

Total abstract views: 79 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 21st April 2018. This data will be updated every 24 hours.

Historical perspective on antipsychotic long-acting injections

  • D. A. W. Johnson (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *